KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Times Interest Earned (2016 - 2020)

Historic Times Interest Earned for Nektar Therapeutics (NKTR) over the last 11 years, with Q2 2020 value amounting to -$120.11.

  • Nektar Therapeutics' Times Interest Earned fell 46616.91% to -$120.11 in Q2 2020 from the same period last year, while for Mar 2021 it was -$619.59, marking a year-over-year decrease of 294855.81%. This contributed to the annual value of -$62.05 for FY2020, which is 20050.01% down from last year.
  • As of Q2 2020, Nektar Therapeutics' Times Interest Earned stood at -$120.11, which was down 46616.91% from -$21.54 recorded in Q1 2020.
  • In the past 5 years, Nektar Therapeutics' Times Interest Earned registered a high of $180.8 during Q2 2018, and its lowest value of -$120.11 during Q2 2020.
  • Over the past 5 years, Nektar Therapeutics' median Times Interest Earned value was -$13.16 (recorded in 2017), while the average stood at -$7.09.
  • In the last 5 years, Nektar Therapeutics' Times Interest Earned crashed by 597731.16% in 2016 and then skyrocketed by 206659.79% in 2018.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Times Interest Earned stood at -$5.79 in 2016, then increased by 26.33% to -$4.27 in 2017, then plummeted by 334.1% to -$18.52 in 2018, then decreased by 9.05% to -$20.2 in 2019, then tumbled by 494.63% to -$120.11 in 2020.
  • Its Times Interest Earned stands at -$120.11 for Q2 2020, versus -$21.54 for Q1 2020 and -$20.2 for Q4 2019.